Results 381 to 390 of about 146,874 (392)

HER2-targeted therapies — a role beyond breast cancer

Nature Reviews Clinical Oncology, 2019
Yung-Jue Bang
exaly  

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Nature Reviews Clinical Oncology, 2009
Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi   +2 more
exaly  

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Lancet, The, 2017
David A Cameron, Evandro de Azambuja, Ian Smith   +2 more
exaly  

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Cancer Cell, 2009
Teemu T Junttila, Gail D Lewis Phillips
exaly  

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2012
José Baselga, Serena Di Cosimo, Evandro de Azambuja   +2 more
exaly  

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

The Lancet Oncology, 2019
K. Tamura, J. Tsurutani, S. Takahashi, H. Iwata, I. Krop, C. Redfern, Y. Sagara, T. Doi, Haeseong Park, R. Murthy, R. Redman, Takahiro Jikoh, Caleb Lee, M. Sugihara, J. Shahidi, A. Yver, S. Modi   +16 more
semanticscholar   +1 more source

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2016
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino   +2 more
exaly  

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly  

Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab

Ca-A Cancer Journal for Clinicians, 2012
exaly  

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Journal of Clinical Oncology, 2005
Francesco Cognetti, Ana Lluch, Kenneth J O'byrne   +2 more
exaly